Enk Alexander H, Becker Jürgen C, Schuler Gerold
Hautklinik der Ruprecht-Karls-Universität Heidelberg.
J Dtsch Dermatol Ges. 2006 Aug;4(8):635-45. doi: 10.1111/j.1610-0387.2006.06033.x.
Immunotherapy has assumed increasing importance in the therapy of malignant melanoma. The main reason is the high immunogenicity of the tumor itself, so that an immune response against the tumor often exists even without immune stimulation. The goal of modern immunotherapeutic approaches is to augment these anti-tumoral immune reactions to fight the tumor. Despite multiple successes, the ultimate breakthrough in the therapy of malignant melanoma has not yet been achieved. This overview summarizes the reasons for this lack of success and highlights future strategies for more successful therapy of malignant melanoma.
免疫疗法在恶性黑色素瘤的治疗中已变得越来越重要。主要原因是肿瘤本身具有高度免疫原性,以至于即使没有免疫刺激,针对肿瘤的免疫反应通常也存在。现代免疫治疗方法的目标是增强这些抗肿瘤免疫反应以对抗肿瘤。尽管取得了多项成功,但恶性黑色素瘤治疗的最终突破尚未实现。本综述总结了未能成功的原因,并强调了未来更成功治疗恶性黑色素瘤的策略。